IRB Study Number 25-020
Status Recruiting
Phase Phase 4
Location U Building - Mellen Center
Institute Neurological Institute
Description
The purpose of this study is to evaluate safety and effectiveness of BRIUMVI® (ublituximab-xiiy), as well as gain insight into the treatment experience in a real-world setting. BRIUMVI® was approved by the FDA in December 2022.
Participation involves evaluation of 6 infusions over 96 weeks of therapy, with study visits being same day as clinical appointments. Activities include screening assessment, data collection, and questionnaires.
Inclusion Criteria
- Age 18+
- Diagnosed with relapsing forms of MS
- No prior BRIUMVI® infusion before study start
Exclusion Criteria
- Recent live or live-attenuated vaccination
- Active infection such as Hepatitis B
- Concurrent participation in other MS trials or treatments
